ATDBio is a leading partner for specialized and large-scale oligonucleotide synthesis for the development of advanced therapeutics. Founded in 2005, ATDBio is singularly focused on nucleic acid chemistry, and provides comprehensive chemical solutions including R&D, method development, and design and synthesis of complex oligonucleotides to help RNA innovators and developers advance their drug programs. The company is headquartered in the United Kingdom, with facilities in both Southampton and Oxford.